NM_004006.3(DMD):c.1A>T (p.Met1Leu)

Prime Editing (PE5max/PEmax) via Dual-AAV delivery is a rationale-driven therapeutic strategy for Duchenne muscular dystrophy targeting the DMD c.1A>T (p.Met1Leu) variant (Pathogenic, missense variant, initiator_codon_variant, intron variant). The editing system (PEmax with engineered pegRNA) search-and-replace editing that directly rewrites the pathogenic transversion back to wild-type without requiring DSBs. Target tissue: Muscle. Therapeutic goal: Correct or bypass pathogenic DMD mutations in skeletal and cardiac muscle to restore sufficient dystrophin expression and stabilize muscle function. Risk profile: off-target Low (prime editing has inherently low off-target rate), delivery complexity Medium, immunogenicity High.

1. Molecular basis: DMD NM_004006.3(DMD):c.1A>T (p.Met1Leu) is classified as Pathogenic (ClinVar variation ID 4774215). Molecular consequence: missense variant, initiator_codon_variant, intron variant. Protein change: M1L. 2. Epidemiology: Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder with an estimated birth prevalence of ~1 in 3,500–5,000 live male births, characterized by onset of muscle weakness in early childhood, loss of ambulation around 9–13 years without effective disease-modifying therapy, 3. Standard of care: Current standard care combines long-term glucocorticoid therapy, multidisciplinary cardiac and respiratory management, and orthopedic and rehabilitative support. Mutation-specific drugs such as ataluren for nonsense mutations and exon-skipping ASOs (e.g., eteplirsen, golodirsen) are available for su 4. Pipeline: Multiple AAV micro-dystrophin gene therapies (e.g., ELEVIDYS, fordadistrogene) have completed Phase I/II and Phase III trials with mixed efficacy and important safety signals; one product has FDA approval with confirmatory studies ongoing. Exon-skipping and read-through agents have completed Phase I 5. Prime editing validation: PEmax (Chen et al. 2021, Cell) enables precise insertions, deletions, and all 12 point mutations without DSBs. Prime Medicine is advancing PE programs into clinical development. LNP and dual-AAV delivery of PE have been demonstrated in preclinical liver and CNS models.

1. No published data specifically correcting DMD c.1A>T (p.Met1Leu) with Prime Editing (PE5max/PEmax); strategy is based on general principles and must be validated preclinically. 3. Dual-AAV delivery requires intein-mediated protein reconstitution with lower efficiency than single-AAV. Pre-existing AAV immunity in the patient population may limit eligibility. 4. Delivery to Muscle tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.